Fintech PR
GTN enlists former Saxo Bank CCO Damian Bunce as new Middle East CEO
DUBAI, UAE, April 4, 2024 /PRNewswire/ — GTN, a global fintech redefining trading and investing for all, is pleased to announce Damian Bunce’s appointment as the CEO of GTN Middle East. Bunce brings over 30 years of unparalleled forex and online securities trading expertise in brokerage and investment banking.
With an extensive career at leading financial services institutions such as IBM, Goldman Sachs, Barclays, and Saxo Bank, Damian Bunce has held numerous C-level positions, showcasing his strategic acumen and industry leadership. Notably, his tenure as Chief Commercial Officer at Saxo Bank exemplifies his ability to drive forward-thinking strategies and navigate complex market landscapes.
Recently, Bunce ran the Trading business at online market maker Exness; during his 3.5-year tenure, the company developed a new B2B capability and broke retail volume records, boasting 4 trillion dollars/month and ranking number 1 in the industry. Subsequently, he assumed the role of Chief Customer Officer, where he excelled in cultivating strong client and media relationships, building the company’s brand and instilling confidence within the financial community.
GTN co-founder and Group CEO Manjula Jayasinghe said: “We are thrilled to have Damian join us in Dubai as CEO of GTN Middle East. His industry and commercial acumen will elevate our success in materialising our goal of being the leading global fintech that makes trading and investing accessible to all.”
In his new role, Bunce will lead GTN’s strategic initiatives in the Middle East, help coordinate global activities across its network of offices, and further cement the company’s commitment to providing innovative trading and investment solutions to a broad range of financial services companies.
Speaking of his appointment, Bunce said, “I’m delighted to join GTN at an exciting time in the company’s history. I look forward to a move back to mainstream B2B and working in a region that has gained global strategic importance for financial services. GTN has a strong leadership team, a market-leading regulated product, an enviable client list, and a high-quality board of investors; the future possibilities are limitless.”
This appointment marks another milestone in GTN’s global expansion journey. It follows a series of strategic hires to fortify its position as the global fintech frontrunner, providing innovative investment and trading solutions for partners, brokers, banks, wealth managers, and fintechs.
About GTN
GTN is a fintech pioneer with decades of success, holding broker-dealer and capital markets services licenses in multiple jurisdictions through subsidiaries. We are committed to empowering brokers, banks, asset managers, and fintechs with scalable and innovative investment and trading solutions that enable access to a comprehensive network of global markets and multiple asset classes, making investment and trading accessible to all. Our investment and trading solutions offer seamless integration with the existing services of regulated financial firms and fintechs via our co-branded front ends and versatile API suite. Inspired by embedded finance, our API suite provides the adaptability to develop bespoke trading/investment applications or incorporate GTN features into existing platforms, enhancing their value proposition. In addition, our comprehensive global trading ecosystem includes best-in-class execution, custody, and post-trade solutions.
We bring together a diverse team of over 400 talented individuals spread across Dubai, Singapore, South Africa, Sri Lanka, the UK, and the US, united by a shared passion and purpose: empowering clients and transforming the accessibility to investment and trading opportunities for all. We are backed by strategic investors IFC, a member of the World Bank Group, and SBI Ventures Singapore Pte. Ltd., a group company of SBI Holdings, Inc., one of the largest financial services firms listed on the Tokyo Stock Exchange. To learn more, visit www.gtngroup.com or follow us on LinkedIn.
Photo – https://mma.prnewswire.com/media/2379432/GTN_1.jpg
Logo – https://mma.prnewswire.com/media/1904122/4631591/GTN_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/gtn-enlists-former-saxo-bank-cco-damian-bunce-as-new-middle-east-ceo-302108297.html
Fintech PR
Multi-Use Bioreactor Market in Pharmaceuticals and Research Institutions to Hit USD 12.26 Billion by 2029, Growing 9.7% Annually | Valuates Reports
BANGALORE, India, March 13, 2025 /PRNewswire/ — Multi Use Bioreactor Market is Segmented by Type (Manual, Automatic, Semi-Automatic), by Application (Pharmaceuticals, Scientific Research Institution).
According to new survey, Global Multi Use Bioreactor Market is projected to reach USD.
12260 Million in 2029, increasing from USD 6415 Million in 2022, with a CAGR of 9.7% during the period of 2023 to 2029.
Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-37Q12337/Global_Multi_Use_Bioreactor_Market
Major Factors Driving the Growth of Multi Use Bioreactor Market:
The multi-use bioreactor market is experiencing sustained growth, driven by advancements in biopharmaceutical production, automation, and process optimization. These systems play a vital role in scaling up biologics manufacturing while maintaining cost efficiency and regulatory compliance. Market players are investing in next-generation bioreactor technologies to enhance productivity and meet evolving industry demands.
The integration of artificial intelligence, real-time monitoring, and hybrid bioprocessing solutions is transforming biomanufacturing practices. As personalized medicine and cell-based therapies gain traction, the demand for flexible and high-performance bioreactors is expected to rise. The continuous expansion of global bioprocessing infrastructure reinforces the market’s long-term growth trajectory, positioning multi-use bioreactors as indispensable assets in pharmaceutical and biotechnology sectors.
Unlock Insights: View Full Report Now! https://reports.valuates.com/market-reports/QYRE-Auto-37Q12337/global-multi-use-bioreactor
TRENDS INFLUENCING THE GROWTH OF THE MULTI USE BIOREACTOR MARKET:
Semi-automatic bioreactors play a crucial role in biopharmaceutical research and industrial fermentation processes by offering a balance between manual control and automation. These systems enable users to adjust key parameters such as temperature, pH, and oxygen levels while leveraging automated controls for consistency. The flexibility of semi-automatic bioreactors makes them ideal for academic institutions, pilot-scale production, and laboratories requiring cost-effective solutions. Their ability to accommodate a wide range of microbial and cell culture processes attracts pharmaceutical companies looking for adaptable production methods. The increasing demand for customized bioproduction, including cell therapy and regenerative medicine, further propels the adoption of semi-automatic bioreactors. These factors drive market growth and expand bioprocessing capabilities globally.
Automatic bioreactors are revolutionizing large-scale biomanufacturing by integrating advanced sensors, AI-driven monitoring, and real-time data analytics. These systems optimize fermentation and cell culture processes, reducing human intervention while ensuring precision and reproducibility. The pharmaceutical industry heavily relies on automatic bioreactors for monoclonal antibody production, vaccine development, and protein synthesis. Their ability to maintain sterile conditions and minimize contamination risks makes them indispensable for biologics manufacturing. The growing trend of continuous bioprocessing and process intensification has further increased demand for automatic bioreactors, enabling high-throughput production. Additionally, biopharma firms are investing in these systems to enhance scalability, reduce operational costs, and streamline regulatory compliance, fueling the expansion of the multi-use bioreactor market.
The pharmaceutical industry is a major driver of the multi-use bioreactor market, as bioreactors are essential for drug discovery, development, and commercial-scale manufacturing. Biopharmaceutical companies use these systems for cell culture applications, vaccine production, and biosimilar development. With the rise of personalized medicine and gene therapy, pharmaceutical firms are shifting toward modular and flexible bioreactor systems to meet evolving production demands. Regulatory agencies emphasize compliance with Good Manufacturing Practices (GMP), encouraging the adoption of high-quality multi-use bioreactors. Additionally, the rapid response to emerging diseases, such as COVID-19, has accelerated investments in bioreactor technology for vaccine research and development. This increasing reliance on bioreactors for pharmaceutical applications significantly contributes to market growth.
The growing prevalence of chronic diseases and the rise of biologics have fueled demand for biopharmaceuticals, driving the need for efficient multi-use bioreactors. As monoclonal antibodies, gene therapies, and biosimilars gain prominence, manufacturers require scalable bioprocessing solutions. Multi-use bioreactors allow efficient production while ensuring consistency and regulatory compliance. Their ability to support various cell lines and microbial cultures enhances flexibility in drug development. This surge in biologics manufacturing directly contributes to market expansion.
Although single-use bioreactors are gaining traction, multi-use bioreactors remain crucial due to their cost efficiency in large-scale production. Many facilities adopt hybrid systems combining single-use and stainless-steel bioreactors to maximize flexibility. Hybrid approaches allow manufacturers to balance cost savings with operational efficiency, reducing turnaround time while maintaining sterility. This transition toward mixed-use systems supports sustainable biomanufacturing and meets evolving industry needs.
The rise of personalized therapies, including CAR-T cell therapies and regenerative medicine, has necessitated adaptable bioprocessing solutions. Multi-use bioreactors support customized production of small-batch biologics tailored to individual patient needs. Their scalability and versatility make them ideal for emerging cell-based therapies. As precision medicine gains momentum, demand for bioreactors catering to specialized manufacturing continues to grow.
While single-use systems dominate small-scale applications, multi-use bioreactors remain cost-effective for high-volume biomanufacturing. Their ability to process large batches of biologics reduces per-unit costs, making them economically viable for commercial production. Established pharmaceutical companies leverage multi-use systems for blockbuster drug manufacturing, ensuring long-term cost savings. This economic advantage reinforces their continued market demand.
Claim Yours Now! https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-37Q12337&lic=single-user
MULTI USE BIOREACTOR MARKET SHARE
North America dominates the market due to the presence of leading biopharma companies, a robust research ecosystem, and significant government funding. Europe follows closely, with stringent regulatory standards and strong biomanufacturing capabilities.
Key Companies:
- Sartorius
- Thermo Fisher Scientific Inc
- General Electric
- Eppendorf
- Merck KGaA
- Pall Corporation
- ZETA
- Pierre Guerin
- Praj Hipurity Systems Limited
- Bioengineering AG
- Infors
- SOLARIS BIOTECHNOLOGY srl
- Bbi-biotech
- PBS Biotech;Inc.
- GEA Group Aktiengesellschaft
- CerCell A/S
Purchase Regional Report: https://reports.valuates.com/request/regional/QYRE-Auto-37Q12337/Global_Multi_Use_Bioreactor_Market
SUBSCRIPTION
We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.
DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS!
– Perfusion Bioreactor market was valued at USD 703.66 Million in 2024 and is anticipated to reach USD 1,153.63 Million by 2031, witnessing a CAGR of 7.19% during the forecast period 2025-2031.
– Lab Scale Bioreactor market was valued at USD 2369 Million in 2023 and is anticipated to reach USD 4337.5 Million by 2030, witnessing a CAGR of 8.6% during the forecast period 2024-2030.
– Single-Use Bioreactors (SUB) Market was valued at USD 220 Million in the year 2024 and is projected to reach a revised size of USD 275 Million by 2031, growing at a CAGR of 3.3% during the forecast period.
– Bioreactors Market
– Pharmaceutical Fermentation Bioreactor market is projected to grow from USD 6256 Million in 2024 to USD 11080 Million by 2030, at a Compound Annual Growth Rate (CAGR) of 10.0% during the forecast period.
– Bioreactors and Fermentors Market
– Cell Culture Bioreactors Market
– Bubble Column Bioreactor Market
– Membrane Bioreactor Systems market was valued at USD 3307.4 Million in 2023 and is anticipated to reach USD 4996.5 Million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
– Fixed Bed Bioreactors Market
– Micro Bioreactors Market revenue was USD 133.9 Million in 2022 and is forecast to a readjusted size of USD 246.5 Million by 2029 with a CAGR of 9.0% during the forecast period (2023-2029).
DISCOVER OUR VISION: VISIT ABOUT US!
Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.
Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that’s why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.
To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources.
GET A FREE QUOTE
Valuates Reports
sales@valuates.com
For U.S. Toll-Free Call 1-(315)-215-3225
WhatsApp: +91-9945648335
Website: https://reports.valuates.com
Blog: https://valuatestrends.blogspot.com/
Pinterest: https://in.pinterest.com/valuatesreports/
Twitter: https://twitter.com/valuatesreports
Facebook: https://www.facebook.com/valuatesreports/
YouTube: https://www.youtube.com/@valuatesreports6753
https://www.facebook.com/valuateskorean
https://www.facebook.com/valuatesspanish
https://www.facebook.com/valuatesjapanese
https://valuatesreportspanish.blogspot.com/
https://valuateskorean.blogspot.com/
https://valuatesgerman.blogspot.com/
https://valuatesreportjapanese.blogspot.com/
Logo: https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg
View original content:
Company announcement No. 578, 2025
CEO Jörg Brinkmann have purchased shares in H+H International A/S
COPENHAGEN, Denmark, March 13, 2025 /PRNewswire/ — H+H International A/S has received notification pursuant to article 19 of EU Regulation no. 596/2014 of the below transaction(s) related to shares or other financial instruments in H+H International A/S made by persons discharging managerial responsibilities in H+H International A/S or persons closely related to them.
|
1.
|
Details of the person discharging managerial responsibilities/person closely associated
|
||
|
a)
|
Name
|
Jörg Brinkmann
|
|
|
2.
|
Reason for the notification
|
||
|
a)
|
Position/status
|
CEO
|
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
|
3.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
H+H International A/S
|
|
|
b)
|
LEI
|
LEI: 3800GJODT6FV8QM841
|
|
|
4.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Shares
DK0015202451
|
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
DKK 110 per share |
2,000
|
||
|
d)
|
Aggregated information
– Aggregated volume
– Aggregated price
|
Aggregated information
2000 shares
DKK 220,000
|
|
|
e)
|
Date of the transaction(s)
|
2025-03-10
|
|
|
f)
|
Place of transaction(s)
|
Copenhagen (XCSE)
|
|
|
1.
|
Details of the person discharging managerial responsibilities/person closely associated
|
||
|
a)
|
Name
|
Jörg Brinkmann
|
|
|
2.
|
Reason for the notification
|
||
|
a)
|
Position/status
|
CEO
|
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
|
3.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
H+H International A/S
|
|
|
b)
|
LEI
|
LEI: 3800GJODT6FV8QM841
|
|
|
4.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Shares
DK0015202451
|
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
DKK 107.6 per share |
2,000 |
||
|
d)
|
Aggregated information
– Aggregated volume
– Aggregated price
|
Aggregated information
2000 shares
DKK 215,200
|
|
|
e)
|
Date of the transaction(s)
|
2025-03-11
|
|
|
f)
|
Place of transaction(s)
|
Copenhagen (XCSE)
|
|
CONTACT:
For further information please contact:
Niclas Bo Kristensen
Head of Investor Relations & Treasury
+45 24 48 03 67
Nbk@hplush.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
578 – Transactions for persons discharging managerial responsibilities |
View original content:https://www.prnewswire.co.uk/news-releases/transactions-for-persons-discharging-managerial-responsibilities-302401339.html
Fintech PR
CBC Summit Expands to Europe, Bringing Crypto Banking, Compliance, and Payments Leaders Together in London on March 17, 2026
WASHINGTON, March 13, 2025 /PRNewswire/ — “CBC Summit is excited to announce the expansion of its highly successful US-based event to London on March 17, 2026.“
Introduced in 2023, CBC Summit USA has become a must-attend annual gathering in Washington, D.C., for crypto banking, compliance, and payments executives; featuring participation from industry leaders such as Coinbase, Kraken, Ledger, Binance, Elliptic, Stripe, Robinhood, Anchorage Digital Bank, Silicon Valley Bank, Ibanera, and BCB Group.
CBC Summit Europe marks a significant step in expanding the event’s global reach, offering professionals across Europe the opportunity to engage in high-level discussions on the latest trends, challenges, and solutions shaping the global crypto banking ecosystem.
CBC Summit Europe will provide a platform for over 100 European industry leaders, executives, and government agencies to engage in high-level discussions on the latest trends, challenges, and solutions shaping the global crypto banking ecosystem.
CBC Summit Europe topics will include:
- The current state of fintech and crypto banking in the UK and Europe – insights into the struggles and solutions to onboarding with crypto friendly banks for fiat on-ramp and off-ramp services in the UK and Europe.
- Building the new Financial Infrastructure – exchanges and partners are building out their own Layer 2 networks to ease transition to DeFi and map out a new financial infrastructure. What comes next?
- Navigating AML Challenges in the FCA & MiCA Era – adapting to evolving anti-money laundering regulations.
- Transforming Global Finance with Stablecoins & Cross-Border Payments – exploring their role in transforming global finance.
- Financial Crime Trends in Crypto & Fintech – What methods are criminals currently employing, and how is financial crime evolving in crypto?
“The expansion of CBC Summit USA to Europe reflects the growing importance of global collaboration in crypto banking, compliance, and payments” said Joshua Radbod, CEO of CBC Summit. “As the industry continues to evolve, bringing together global leaders from different regulatory environments is crucial for shaping its future.”
Registration & More Information: Registration is now open, and attendees are encouraged to secure their spots in advance. For more details on speakers, sessions, and sponsorship opportunities, visit https://www.cbcsummit.io/europe
About CBC Team: The CBC Team specializes in creating and operating events that address banking, compliance, and payments challenges in emerging industries. For more information, visit CBC Summit.
Media Contact: info@cbcsummit.io
View original content:https://www.prnewswire.co.uk/news-releases/cbc-summit-expands-to-europe-bringing-crypto-banking-compliance-and-payments-leaders-together-in-london-on-march-17-2026-302400124.html
-
Fintech6 days agoFintech Pulse: Your Daily Industry Brief – March 7, 2025 | Wise, Visa, Cadence, Unicredit, Aion Bank, Vodeno
-
Fintech7 days agoFintech Pulse: Your Daily Industry Brief – March 6, 2025 – Featuring Bolt, WSFS Bank, Greenlight, Bkash, Huawei, Meliuz
-
Fintech6 days agoHyPerform Receives ‘Excellence in Fintech’ Award at ET NOW Business Conclave & Awards 2025
-
Fintech PR6 days agoInnocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited
-
Fintech PR6 days agoMinesto selected to participate in GIA (Global Innovation Accelerator) programme by Swedish Energy Agency
-
Fintech PR6 days agoElliptic Data used by US Secret Service in Investigation into $96 Billion Russian Crypto Exchange Garantex
-
Fintech PR6 days agoApollo Group TV Expands Payment Options Making Premium Streaming More Accessible In 2025
-
Fintech3 days agoFintech Pulse: Your Daily Industry Brief – March 10, 2025 | Finovifi, Modern Banking Systems, France Flowdesk, Fintech Galaxy, ProgressSoft, Finory Investment, 1337 Ventures